IQVIA Holdings Inc. $IQV Shares Purchased by Vulcan Value Partners LLC

Vulcan Value Partners LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 680,933 shares of the medical research company’s stock after buying an additional 12,177 shares during the quarter. IQVIA makes up 2.4% of Vulcan Value Partners LLC’s holdings, making the stock its 13th biggest holding. Vulcan Value Partners LLC’s holdings in IQVIA were worth $129,914,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Physician Wealth Advisors Inc. increased its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. grew its position in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the period. Atlantic Union Bankshares Corp acquired a new stake in IQVIA during the third quarter worth $36,000. Asset Dedication LLC raised its position in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares during the period. Finally, Rothschild Investment LLC grew its holdings in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. Truist Financial reduced their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday. Mizuho set a $266.00 price target on shares of IQVIA in a research note on Friday, January 9th. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $235.20.

IQVIA Price Performance

IQVIA stock opened at $165.63 on Monday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The firm has a market cap of $28.11 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.37. The company’s 50 day moving average is $217.61 and its two-hundred day moving average is $208.66.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.